{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:27Z","timestamp":1786121907000,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xkme.2026.101415","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:25:17Z","timestamp":1779812717000},"page":"101415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic Review and Methodological Meta-Analysis"],"prefix":"10.1016","volume":"8","author":[{"given":"Fella","family":"Chennou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Strader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Beaubien-Souligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-2670","authenticated-orcid":false,"given":"Jean-Maxime","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s13054-022-04223-6","article-title":"Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis","volume":"26","author":"Pan","year":"2022","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13613-024-01360-9","article-title":"Biomarkers in acute kidney injury","volume":"14","author":"Ostermann","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib3","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"10","key":"10.1016\/j.xkme.2026.101415_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19209","article-title":"Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement","volume":"3","author":"Ostermann","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.xkme.2026.101415_bib5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.kint.2016.02.027","article-title":"Application of new acute kidney injury biomarkers in human randomized controlled trials","volume":"89","author":"Parikh","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13054-024-04877-4","article-title":"Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials","volume":"28","author":"Legrand","year":"2024","journal-title":"Crit Care"},{"key":"10.1016\/j.xkme.2026.101415_bib7","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.xkme.2026.101415_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","article-title":"Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)","author":"Higgins","year":"2019","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13054-018-2021-1","article-title":"Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial)","volume":"22","author":"Lumlertgul","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.xkme.2026.101415_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/srep41300","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) fails as an early predictor of contrast induced nephropathy in chronic kidney disease (ANTI-CI-AKI study)","volume":"7","author":"Ribitsch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xkme.2026.101415_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcrc.2017.08.029","article-title":"The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study","volume":"43","author":"Srisawat","year":"2018","journal-title":"J Crit Care"},{"issue":"20","key":"10.1016\/j.xkme.2026.101415_bib13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.2016.5828","article-title":"Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial","volume":"315","author":"Zarbock","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.xkme.2026.101415_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/SLA.0000000000002485","article-title":"Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study","volume":"267","author":"G\u00f6cze","year":"2018","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.xkme.2026.101415_bib15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00134-016-4670-3","article-title":"Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial","volume":"43","author":"Meersch","year":"2017","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1016\/j.xkme.2026.101415_bib16","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/ndt\/gfy186","article-title":"Urinary [TIMP-2]\u00b7[IGFBP7]-guided randomized controlled intervention trial to prevent acute kidney injury in the emergency department","volume":"34","author":"Schanz","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.xkme.2026.101415_bib17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.xkme.2026.101415_bib18","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.03470316","article-title":"Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade","volume":"11","author":"Palevsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.xkme.2026.101415_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xkme.2026.101415_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/ALN.0000000000001051","article-title":"Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g\/dl","volume":"124","author":"Lee","year":"2016","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.xkme.2026.101415_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjmed.2019.07.041","article-title":"CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction","volume":"133","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.xkme.2026.101415_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.707328","article-title":"Folic acid attenuates contrast-induced nephropathy in patients with hyperhomocysteinemia undergoing coronary catheterization: a randomized controlled trial","volume":"8","author":"Peng","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028683","article-title":"Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: a CONSORT-compliant randomized controlled trial","volume":"101","author":"Ma","year":"2022","journal-title":"Med (Baltim)"},{"issue":"7","key":"10.1016\/j.xkme.2026.101415_bib24","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2666-7568(21)00092-1","article-title":"Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people","volume":"2","author":"Hanlon","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.8818","article-title":"Accuracy of event rate and effect size estimation in major cardiovascular trials: a systematic review","volume":"7","author":"Olivier","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/CCM.0000000000001479","article-title":"Effect of perioperative goal-directed hemodynamic resuscitation therapy on outcomes following cardiac surgery: a randomized clinical trial and systematic review","volume":"44","author":"Osawa","year":"2016","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.xkme.2026.101415_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apha.12764","article-title":"Biomarkers in acute kidney injury\u2014pathophysiological basis and clinical performance","volume":"219","author":"Schrezenmeier","year":"2017","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"10.1016\/j.xkme.2026.101415_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/medicina58030340","article-title":"Acute kidney injury: biomarker-guided diagnosis and management","volume":"58","author":"Yoon","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.xkme.2026.101415_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/UGEZ4120","article-title":"Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis","volume":"26","author":"Brazzelli","year":"2022","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.xkme.2026.101415_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/cc11159","article-title":"Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial","volume":"16","author":"Pickkers","year":"2012","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.xkme.2026.101415_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/TP.0000000000003255","article-title":"Renal function improvement following ANG-3777 treatment in patients at high risk for delayed graft function after kidney transplantation","volume":"105","author":"Bromberg","year":"2021","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.xkme.2026.101415_bib32","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial","volume":"202","author":"Bellomo","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101415_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1213\/ANE.0000000000005458","article-title":"Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI-multicenter randomized controlled trial","volume":"133","author":"Zarbock","year":"2021","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ekir.2025.01.035","article-title":"Early and sensitive detection of cisplatin-induced kidney injury using novel biomarkers","volume":"10","author":"Strader","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"21","key":"10.1016\/j.xkme.2026.101415_bib35","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1001\/jama.2011.713","article-title":"Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses","volume":"305","author":"Ioannidis","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.xkme.2026.101415_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00407","article-title":"Review of statistical methods for biomarker-driven clinical trials","volume":"3","author":"Simon","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101415_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/biostatistics\/kxt010","article-title":"Adaptive enrichment designs for clinical trials","volume":"14","author":"Simon","year":"2013","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.xkme.2026.101415_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajodo.2021.10.008","article-title":"The self-fulfilling prophecy of post-hoc power calculations","volume":"161","author":"Christogiannis","year":"2022","journal-title":"Am J Orthod Dentofacial Orthop"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:07:18Z","timestamp":1786086438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2590059526001779"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101415","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic Review and Methodological Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101415"}}